PMID- 30410039
OWN - NLM
STAT- MEDLINE
DCOM- 20191216
LR  - 20211204
IS  - 1572-0241 (Electronic)
IS  - 0002-9270 (Linking)
VI  - 114
IP  - 2
DP  - 2019 Feb
TI  - Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A 
      Prospective Observational Study.
PG  - 250-257
LID - 10.1038/s41395-018-0383-2 [doi]
AB  - BACKGROUND: Data are sparse on treatment of chronic hepatitis C virus (HCV) in 
      cancer patients. We evaluated the efficacy and safety of sofosbuvir-based therapy 
      (SOFBT) in cancer patients. METHODS: Patients treated with SOFBT at our center 
      during 2014-2017 were included in a prospective observational study. Efficacy 
      [sustained virologic response at 12 weeks after the end of treatment (SVR12)], 
      cancer-related outcomes and adverse events (AEs) were assessed. RESULTS: We 
      included 153 patients. Most were men (109; 71%), white (92; 60%), non-cirrhotic 
      (105; 69%), and with HCV genotype 1 (110; 72%). The most common cancers were 
      hepatocellular carcinoma (HCC) (27; 18%) and multiple myeloma (14; 9%). The 
      overall SVR12 rate was 91% (128/141). SVR12 was 100% in patients treated with 
      ledipasvir/sofosbuvir for 8 weeks. Of the 32 patients initially excluded from 
      cancer clinical trials because of HCV, 27 (84%) were granted cancer therapy 
      access after starting SOFBT. Six patients with indolent non-Hodgkin's lymphoma 
      (NHL) received SOFBT without cancer treatment. Two achieved complete remission, 
      one had partial remission, and two had stable cancer. Within 6 months after 
      SOFBT, 5% (6/121) of patients in remission or with stable cancer, had progression 
      or recurrence (two with HCC and one each with esophageal cancer, 
      cholangiocarcinoma, NHL, and tonsillar cancer). No de novo HCCs occurred. AEs 
      were most commonly grade 1-2 (90%). CONCLUSIONS: SOFBT in HCV-infected cancer 
      patients is effective and safe, may permit access to investigational cancer 
      therapy expanding treatment options, may induce remission of NHL, and may be used 
      for 8 weeks.
FAU - Torres, Harrys A
AU  - Torres HA
AD  - Departments of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
AD  - Departments of Gastroenterology, Hepatology and Nutrition, The University of 
      Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Economides, Minas P
AU  - Economides MP
AD  - Departments of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
AD  - Department of Internal Medicine, University of Texas School of Health Sciences at 
      Houston, Houston, Texas, USA.
FAU - Angelidakis, Georgios
AU  - Angelidakis G
AD  - Departments of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Hosry, Jeff
AU  - Hosry J
AD  - Departments of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Kyvernitakis, Andreas
AU  - Kyvernitakis A
AD  - Departments of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
AD  - Department of Internal Medicine, Allegheny General Hospital, Houston, Texas, USA.
FAU - Mahale, Parag
AU  - Mahale P
AD  - Departments of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
AD  - Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and 
      Genetics, National Cancer Institute, Houston, Texas, USA.
FAU - Jiang, Ying
AU  - Jiang Y
AD  - Departments of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Miller, Ethan
AU  - Miller E
AD  - Departments of Gastroenterology, Hepatology and Nutrition, The University of 
      Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Blechacz, Boris
AU  - Blechacz B
AD  - Departments of Gastroenterology, Hepatology and Nutrition, The University of 
      Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Naing, Aung
AU  - Naing A
AD  - Departments of Investigational Cancer Therapeutics, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas, USA.
FAU - Samaniego, Felipe
AU  - Samaniego F
AD  - Departments of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas, USA.
FAU - Kaseb, Ahmed
AU  - Kaseb A
AD  - Departments of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas, USA.
FAU - Raad, Issam I
AU  - Raad II
AD  - Departments of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Granwehr, Bruno P
AU  - Granwehr BP
AD  - Departments of Infectious Diseases, Infection Control and Employee Health, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Antiviral Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Carbamates)
RN  - 0 (Fluorenes)
RN  - 0 (Heterocyclic Compounds, 4 or More Rings)
RN  - 0 (Imidazoles)
RN  - 0 (Pyrrolidines)
RN  - 013TE6E4WV (ledipasvir)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - 9008-11-1 (Interferons)
RN  - 9WS5RD66HZ (Simeprevir)
RN  - HG18B9YRS7 (Valine)
RN  - KCU0C7RS7Z (velpatasvir)
RN  - LI2427F9CI (daclatasvir)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
CIN - Am J Gastroenterol. 2019 Feb;114(2):207-208. PMID: 30676362
MH  - Aged
MH  - Antiviral Agents/*therapeutic use
MH  - Benzimidazoles/therapeutic use
MH  - Breast Neoplasms/complications
MH  - Carbamates/therapeutic use
MH  - Carcinoma, Hepatocellular/complications
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fluorenes/therapeutic use
MH  - Head and Neck Neoplasms/complications
MH  - Hepatitis C, Chronic/complications/*drug therapy
MH  - Heterocyclic Compounds, 4 or More Rings/therapeutic use
MH  - Humans
MH  - Imidazoles/therapeutic use
MH  - Interferons/therapeutic use
MH  - Liver Neoplasms/complications
MH  - Lymphoma, Non-Hodgkin/complications
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/complications
MH  - Neoplasms/*complications
MH  - Polyethylene Glycols/therapeutic use
MH  - Prospective Studies
MH  - Pyrrolidines
MH  - Ribavirin/therapeutic use
MH  - Simeprevir/therapeutic use
MH  - Sofosbuvir/*therapeutic use
MH  - Sustained Virologic Response
MH  - Valine/analogs & derivatives
EDAT- 2018/11/10 06:00
MHDA- 2019/12/18 06:00
CRDT- 2018/11/10 06:00
PHST- 2018/11/10 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2018/11/10 06:00 [entrez]
AID - 10.1038/s41395-018-0383-2 [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2019 Feb;114(2):250-257. doi: 10.1038/s41395-018-0383-2.